Devonian Health Group Inc. (CVE:GSD – Get Free Report)’s stock price shot up 10.4% on Wednesday . The company traded as high as C$11.15 and last traded at C$11.15. Approximately 2,138 shares were traded during trading, an increase of 79% from the average session volume of 1,194 shares. The stock had previously closed at C$10.10.
Devonian Health Group Stock Up 10.4%
The company has a debt-to-equity ratio of 16.36, a current ratio of 1.07 and a quick ratio of 7.82. The stock’s fifty day simple moving average is C$8.73 and its 200-day simple moving average is C$10.68. The stock has a market cap of C$31.01 million, a P/E ratio of -4.96 and a beta of 0.42.
About Devonian Health Group
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.
See Also
- Five stocks we like better than Devonian Health Group
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
